This report, published by the Welsh Government and NHS Wales, provides an overview of liver disease in Wales, and gives details of the actions currently underway to tackle liver disease, including hepatitis C.
Resources
Drug services professional
Around half of current injecting drug users will have hepatitis C, although this prevalence rate varies across the country. Find here tools, resources and other relevant documents to help drugs service staff raise awareness of hepatitis C amongst service users, and improve testing and access to care.
Showing 261 to 270 of 291 resources
-
Together for Health: Liver Disease Annual Report 2016 - Setting the Baseline
UK, Wales Reports & Research PDF -
Treatment Guidance for Patients with Hepatitis C in Greater Manchester
This document provides guidance on treatment for patients with Hepatitis C in Greater Manchester. It defines responses to treatment, runs through treatment protocols, types of treatment for various kinds of patient, and protocols for managing treatment side effects.North West 04 Nov 2010 Reports & Research, Tools & Templates PDF -
Tri-borough Substance Misuse and Sexual Health Blood Borne Virus Strategy 2014-2016: Hammersmith & Fulham, Royal Borough of Kensington & Chelsea, and Westminster City Council
This substance misuse and sexual health blood borne virus strategy has been produced jointly by the tri-borough of Hammersmith and Fulham, the Royal Borough of Kensington and Chelsea and Westminster City Council to ensure that prevention, diagnosis and treatment of hepatitis C has an increased focus.Greater London Jul 2014 Strategy & Planning PDF -
Turning Evidence into Practice: Improving access to, and completion of, hepatitis C treatment
This briefing, produced by Public Health England, has practical advice for commissioners and services on improving access to, and completion of, hepatitis C treatment. It provides an overview of the key local issues that local providers and commissioners of drug and hepatitis C treatment should consider when commissioning and delivering services, and contains a series of prompts and examples of good practice.UK, England Jul 2015 Case study, Tools & Templates, Strategy & Planning PDF -
Understanding the pathway: barriers to data collection and onward referral to specialist hepatitis C services for PWID in London
This report, from the London Joint Working Group on Substance Use and Hepatitis C, examines barriers to data collection and onward referral to specialist hepatitis C services for people who inject drugs in London.England, Greater London Reports & Research PDF -
Understanding the Sexual Health and Blood Borne Virus Risk Behaviours of Defined 'at risk' Groups
This report outlines the findings of research with drug users and the staff that support them related to harms associated with chemsex, transactional sex; and the use of image and performance enhancing drugs (IPEDs). Twos aims of the report were to describe the risk-taking behaviours in relation to drug taking, sexual health and transmission of BBV (blood borne virus) of the three target groups and inform the development of a training programme for services providers on sexual health and blood borne viruses for the three defined groups.Scotland 07 Sep 2020 Reports & Research PDF -
Unlinked anonymous HIV and viral hepatitis monitoring among PWID: 2017 report
This report presents an overview of the trends between 2006 and 2016 for HIV, hepatitis B, hepatitis C and risk behaviours from the ongoing Unlinked Anonymous Monitoring Survey, which is targeted at people who inject psychoactive drugs, such as heroin, crack cocaine and amphetamines.UK Reports & Research PDF -
Unlinked Anonymous Monitoring (UAM) Survey of HIV and viral hepatitis among PWID: 2020 report
The 2020 edition of the Unlinked Anonymous Monitoring (UAM) Survey of HIV and viral hepatitis among PWID contains a number of relevant updates on hepatitis C among injecting drug users, including: • The proportion of UAM participants with antibodies to hepatitis C (HCV) (i.e. ever infected) who have markers of chronic infection (RNA) has decreased from 58% in 2011 when it was first measured to 42% in 2019; this corresponds with the timing of the scale-up of direct acting antiviral treatment against HCV among PWIDUK 06 Oct 2020 Reports & Research PDF -
Webinar recording: HCV Action National Hepatitis C ODN Stakeholder Webinar 2021
Presentations from the HCV Action National Hepatitis C ODN Stakeholder Webinar 2021, featuring updates from NHS England HCV Elimination Programme Leads Professor Graham Foster and Mark Gillyon-Powell, the UK Health Security Agency's Dr Monica Desai and HCV Action Chair Professor Stephen Ryder.England 04 Nov 2021 Reports & Research, Strategy & Planning Video -
Webinar recording: Hepatitis C in community pharmacies
Forming part of the HCV Action National Hepatitis C ODN Stakeholder Webinar series, this webinar looked at hepatitis C in community pharmacies, with presentations from NHS England HCV Elimination Programme Lead Mark Gillyon-Powell and clinical experts Dr Ahmed Elsharkawy, Dr Ryan Buchanan and Helen Boothman.England 17 Nov 2021 Training, Reports & Research, Strategy & Planning Video